arGEN-X
antibody technology
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available,...Homepage: http://www.argen-x.com/
Total money raised: $55.2M
HQ
3015 Dr Molewaterplein 50Rotterdam
NLD
Phone: +31 (0)10 70 38 441
Updated on Dec 5, 2012
arGEN-X at CrunchBase
arGEN-X at CrunchBase
December, 2011
arGEN-X raised $37.1M in a Series B round from OrbiMed Advisors, Forbion Capital Partners, Credit Agricole Private Equity, LSP BioVentures, Erasmus MC Biomedical Fund, and Seventure Partners
arGEN-X Closes €27.5M Series B Funding Round 
finsmes.com
February, 2010
arGEN-X raised $4.5M in a Series A round from Credit Agricole Private Equity, Forbion Capital Partners, Life Sciences Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund, and Thuja Capital
arGEN-X, BV: Series A $4.5M 
onbiovc.com
September, 2009
arGEN-X raised $13.6M in a Series A round from Forbion Capital Partners, KBC Private Equity, BioGeneration Ventures, and Erasmus MC Biomedical Fund
arGEN-X gins $13.6M in new funds for mAB work 
fiercebiotech.com